论文部分内容阅读
目的分析地特胰岛素联合瑞格列奈治疗2型糖尿病的临床疗效及安全性。方法研究对象选取本院2015年1月至2015年12月收治的90例2型糖尿病患者,随机将患者分为研究组和对照组各45例。对照组患者使用预混人胰岛素混合液注射治疗,研究组患者接受地特胰岛素联合瑞格列奈治疗。对两组患者的血糖水平、糖化血红蛋白等指标进行观察对比。结果研究组患者的血糖较治疗前明显下降(P<0.05),其中血糖变异系数对比对照组患者差异显著(P<0.05);研究组患者治疗后的不低血糖发生率低于对照组,组间差异结果同样具有统计学意义(P<0.05)。结论地特胰岛素联合瑞格列奈治疗2型糖尿病的疗效较好、不良反应发生率较低,具有较高的应用价值。
Objective To analyze the clinical efficacy and safety of insulin detemir plus repaglinide in type 2 diabetes mellitus. Methods Subjects Totally 90 patients with type 2 diabetes admitted from January 2015 to December 2015 in our hospital were randomly divided into study group (45 cases) and control group (45 cases). Patients in the control group were treated with a premixed insulin mix and patients in the study group were treated with insulin detemir plus repaglinide. The two groups of patients with blood glucose levels, glycosylated hemoglobin and other indicators were observed and compared. Results The blood glucose in study group was significantly lower than that before treatment (P <0.05), and the coefficient of variation in blood glucose was significantly different from that in control group (P <0.05). The incidence of non-hypoglycemia in study group was lower than that in control group The difference between the two groups was also statistically significant (P <0.05). Conclusion The combination of detemir insulin and repaglinide is effective in treating type 2 diabetes mellitus, with a low incidence of adverse reactions and high application value.